Clinical Trial Update: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update indicates a study of Olaparib in combination with ASTX727 for BRCA1/2- and homologous recombination deficiency-mutated tumors is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Lynparza (olaparib)

Snippet

Sponsor: Pamela Munster | Conditions: BRCA1 Mutation, BRCA2 Mutation | Phase 1 | Status: RECRUITING